Pharmaceutical research and development expenditures are undergoing a targeted re-allocation toward target-validated RNA and oligonucleotide therapeutics. The strategic shift aims to improve clinical trial success rates and compress drug discovery timelines.
Pipeline Optimization
Late-stage trial failure rates in broad-spectrum oncology have prompted research leads to prioritize modalities with higher mechanism-of-action certainty. Contract development and manufacturing organizations (CDMOs) report increased backlogs for lipid nanoparticle synthesis lines.